Identifying premenopausal patients with early-stage hormone receptor–positive breast cancer at minimal risk of distant recurrence by breast cancer index
This study confirmed prognostic ability of the minimal-risk BCI cutpoint to classify patients estimated to have minimal-risk of distant recurrence within 10 years among premenopausal patients treated for hormone-receptor-positive node-negative breast cancer, providing relevant information for personalizing adjuvant endocrine therapy. SOFT: (clinicaltrials.gov NCT00066690) TEXT: (clinicaltrials.gov NCT00066703).
Authors
- Barbara Walley
- Prudence A. Francis (ORCID: https://orcid.org/0000-0002-7207-9286)
- Ruth O’Regan
- Kai Treuner (ORCID: https://orcid.org/0009-0006-3443-3578)
- Gini F. Fleming
- Giuseppe Viale
- Olivia Pagani
- Sherene Loi
- Marco Colleoni
- Yue Ren
- Patrizia Dell’Orto
- Meredith M. Regan
- Yi Zhang
Institutions
- Queen's University (CA)
- Peter MacCallum Cancer Centre (AU)
- University of Chicago Medical Center (US)
- Biothera (United States) (US)
- Dana-Farber Cancer Institute (US)
- Hologic (United States) (US)
- Dana-Farber/Harvard Cancer Center (US)
- Swiss Group For Clinical Cancer Research (CH)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- International Breast Cancer Study Group (CH)
- University of Rochester (US)
- European Institute of Oncology (IT)
Publication Details
- Journal
- The Breast
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1016/j.breast.2026.104714
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00